Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Cronin-Fenton DP, Lash TL.

Expert Rev Clin Pharmacol. 2011 May;4(3):363-77. doi: 10.1586/ecp.11.18. Review.

2.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S.

J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15.

3.

Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States.

Yong M, Schwartz SM, Atkinson C, Makar KW, Thomas SS, Stanczyk FZ, Westerlind KC, Newton KM, Holt VL, Leisenring WM, Lampe JW.

J Steroid Biochem Mol Biol. 2011 Mar;124(1-2):10-8. doi: 10.1016/j.jsbmb.2010.12.014. Epub 2010 Dec 28.

4.

Genotype-guided tamoxifen therapy: time to pause for reflection?

Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S.

Lancet Oncol. 2009 Aug;10(8):825-33. doi: 10.1016/S1470-2045(09)70030-0. Review.

5.

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.

Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D.

Ann N Y Acad Sci. 2009 Feb;1155:99-111. doi: 10.1111/j.1749-6632.2009.04114.x. Review.

6.

Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.

Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, Lazarus P.

Cancer Res. 2009 Mar 1;69(5):1892-900. doi: 10.1158/0008-5472.CAN-08-3708. Epub 2009 Feb 24.

7.

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise.

Møller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT; Danish Breast Cancer Cooperative Group.

Acta Oncol. 2008;47(4):506-24. doi: 10.1080/02841860802059259.

PMID:
18465317
8.

Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary.

Blichert-Toft M, Christiansen P, Mouridsen HT.

Acta Oncol. 2008;47(4):497-505. doi: 10.1080/02841860802068615.

PMID:
18465316
9.

Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.

Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P.

Drug Metab Dispos. 2007 Nov;35(11):2006-14. Epub 2007 Jul 30.

10.

Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.

Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P.

Drug Metab Dispos. 2007 Oct;35(10):1942-8. Epub 2007 Jul 9.

11.

The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.

Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C.

Clin Pharmacol Ther. 2007 Mar;81(3):392-400.

PMID:
17339869
12.

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.

Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S.

Breast Cancer Res. 2007;9(1):R7.

13.

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA.

Clin Pharmacol Ther. 2006 Jul;80(1):61-74.

14.

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.

Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB.

Breast Cancer Res Treat. 2005 Jun;91(3):249-58.

15.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
16.

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

Lim YC, Desta Z, Flockhart DA, Skaar TC.

Cancer Chemother Pharmacol. 2005 May;55(5):471-8. Epub 2005 Feb 1.

PMID:
15685451
17.

Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases.

Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, Watabe T.

Biochem Pharmacol. 2002 May 15;63(10):1817-30.

PMID:
12034366
18.

The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes.

Albert C, Vallée M, Beaudry G, Bélanger A, Hum DW.

Endocrinology. 1999 Jul;140(7):3292-302.

PMID:
10385426
19.

Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene.

Lévesque E, Beaulieu M, Green MD, Tephly TR, Bélanger A, Hum DW.

Pharmacogenetics. 1997 Aug;7(4):317-25.

PMID:
9295060

Supplemental Content

Support Center